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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of rapid initiation of ART on treatment outcomes and mortality in PLWH.
B A C K G R O U N D
Description of the condition
At the end of 2016, there were approximately 36.7 million people
living with HIV worldwide, most of them in low- and middle-
income countries (LMICs) (WHO 2017b). Although HIV infec-
tion continues to be a leading global cause of death and disability,
mortality from the virus has almost halved in the past decade due
to the rapid expansion of antiretroviral therapy (ART) (UNAIDS
2016).
The latest guidelines of the World Health Organization (WHO)
recognize that people living with HIV/AIDS (PLWH) need to
receive a continuum (or cascade) of care in order to fully benefit
from ART (WHO 2016), and highlight the importance of all
elements of HIV care, including HIV diagnosis, engagement in
HIV care, provision of ART, and achievement of viral suppression
(Gardner 2011; MacCarthy 2015; Okeke 2014). For this reason,
the Joint United Nations Programme on HIV/AIDS (UNAIDS)
introduced, in 2014, the 90-90-90 goals, which aim to diagnose
90% of all people infected with the virus, reach 90% of ART
uptake in those diagnosed with HIV, and achieve a 90% rate of
viral suppression among those receiving ART by 2020 (UNAIDS
2014).
Substantial international efforts will be needed to achieve these
targets, as only 53% of PLWH were receiving ART in 2016
(UNAIDS 2016). One of the main challenges is attrition in HIV
services during the period of linkage from HIV diagnosis to initi-
ating ART (Govindasamy 2014; Losina 2010; Rosen 2011). Dis-
engagement from care while PLWH are being prepared to initi-
ate ART is particularly relevant in sub-Saharan Africa, where it is
estimated that only 57% of those diagnosed with HIV are linked
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to care (Kranzer 2012). Many affected individuals who disengage
from services during this period return only when they have de-
teriorated clinically and immunologically; this results in higher
morbidity and mortality when they do start ART (Fairall 2008;
Grinsztejn 2014; HMC 2015). One of the contributing factors
to poor engagement in care identified in the literature is the delay
in starting ART (Clouse 2013). A longitudinal study in Ethiopia
conducted between 2005 and 2013 estimated that 52% of PLWH
waited over a month to start ART once they were classified as eli-
gible according to the CD4 criteria and national guidelines (Teklu
2017). Other studies carried out in sub-Saharan African coun-
tries have found similar results (Bassett 2010; Lawn 2006; Reddy
2016). The reasons why ART initiation is frequently delayed are
complex and involve structural, social, and psychological factors
(Hoehn 2017; Wachira 2014). For example, lack of appropriate
healthcare infrastructures or constrains involved in attending the
several clinic visits that are often required before ART is offered
(Govindasamy 2012).
The WHO now recommends universal ART, irrespective of CD4
cell count and clinical stage (WHO 2016). Asymptomatic PLWH
with higher CD4 cell counts have been shown to adhere poorly to
ART (Adakun 2013), therefore retention in care and ART adher-
ence are critically important.
One proposed intervention for improving linkage and retention of
PLWH inHIV care is rapid ART initiation (starting the therapy as
soon as possible after ART eligibility, normally within seven days
of HIV diagnosis) (Chan 2016; Pilcher 2017). PLWH considered
eligible for ART are normally required to attend HIV services
several times for counselling andmedical evaluation before starting
treatment. It is argued that expediting ART could potentially lead
to earlier viral suppression in the medium- and long-term through
improved uptake and adherence to ART (Hoenigl 2016; Pilcher
2017; Wilkinson 2015).
There remains, however, uncertainty about the acceptability of
rapid ART initiation and its effects on morbidity and long-term
treatment outcomes (Mbonye 2016). Some concerns include:
poor ART adherence with rapid ART initiation, since PLWHmay
not receive sufficient or adequate adherence counselling/educa-
tion, or both; pill burden due to other concurrent comorbidities
or conditions requiring urgent treatment (for example, tubercu-
losis) (Nachega 2014); and immune reconstitution inflammatory
syndrome (IRIS), especially in individuals with advanced disease
(CD4 counts < 200 cells/mm³) (Uthman 2015). Rapid ART initi-
ation could be particularly relevant for PLWH with advanced dis-
ease, as they are at higher risk of mortality and morbidity (Hakim
2017). However, this cohort of individuals are also at higher risk
of IRIS and, therefore, rapid ART should be considered in the
context of differentiated care, in which they receive a comprehen-
sive package of care that includes, among other factors, screen-
ing for opportunistic infections (for example, cryptococcus anti-
gen), co-trimoxazole prophylaxis, and more intensive adherence
and follow-up support (Mfinanga 2015; WHO 2016). It is also
important to acknowledge that some of these individuals may not
be eligible for rapid ART initiation if they are found to have signs
and symptoms of opportunistic infections (for example, tubercu-
losis or cryptococcal meningitis). In these cases, ART initiation
should be delayed according to themost current guidelines (WHO
2017a).
In order to evaluate the uptake, efficacy, and safety of rapid ART
initiation compared with delayed ART initiation it is essential
to consolidate findings from randomized controlled trials (RCTs)
evaluating this intervention.
Description of the intervention
The current standard of care post-HIV diagnosis varies across ar-
eas and settings according to the local context (MacCarthy 2015).
Countries often include in their national guidelines structural
and individual interventions aimed to improve linkage. These in-
clude: integration of services, point-of-care CD4 cell count, post-
test counselling, peer support, support with HIV disclosure, and
addressing any psychosocial barriers identified (NASCOP 2016;
NCASC 2009; NDOHSA 2015; Wynberg 2014). Pre-ART care
includes a comprehensive baseline assessment that often involves a
clinical and a psychosocial assessment (MoH 2016). Thesemay in-
clude several steps such as: physical examination, laboratory tests,
opportunistic infection screening, nutritional status assessment,
counselling, health insurance evaluation, and education sessions
(NDOHSA 2015; Pilcher 2017). These interventions are often
carried out over several visits to HIV services, which means that
ART initiation is often delayed for several weeks after PLWH are
considered eligible for ART (Lawn 2006; Teklu 2017).
High rates of disengagement from care have been reported during
this period (Rosen 2011). In order to expedite this process and
minimize losses to follow-up, more rapid ART initiation has been
proposed.
For the purposes of this Cochrane Review, we define rapid ART as
offering the therapy within seven days after the PLWH is consid-
ered eligible for therapy. According to current guidelines, PLWH
are considered eligible for ART on the same day as diagnosis un-
less they are found to have signs or symptoms of opportunistic
infections such as tuberculosis or cryptococcal meningitis. With
rapid ART, PLWH may receive usual care, but some of the inter-
ventions that form part of pre-ART care are delivered on the same
day or within a few days of HIV diagnosis. These include, among
others, screening for tuberculosis, physical examination, and an
initial counselling and education session (Labhardt 2016; Pilcher
2017; Rosen 2016).
How the intervention might work
Expediting the initiation of ART could improve engagement in
care by simplifying and reducing the number of visits a PLWH
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has to make to HIV services. Delaying ART has been identified in
the literature as major contributor to disengagement, particularly
in LMICs (Govindasamy 2014).
The HIV continuum of care is a complex process in which every
step is influenced by multiple factors, as illustrated in our con-
ceptual model (see Figure 1). This figure shows how the feasibil-
ity of rapid ART initiation depends on various health system and
provider factors, such as staffing levels, skills, infrastructure, and
equipment, which vary across settings (Attawell 2003).
Figure 1. Conceptual model of factors influencing the HIV care continuum. Abbreviations: PLWH: people
living with HIV, ART: antiretroviral therapy, IRIS: immune reconstitution inflammatory syndrome
Uptake of ART is also influenced by various factors (Bolsewicz
2015). Rapid ART could improve uptake of the therapy by reduc-
ing the number of PLWH lost to follow-up in the period of link-
age from HIV diagnosis to ART commencement (Pilcher 2017;
Rosen 2016). However, as Figure 1 shows, uptake of ART is also
influenced by social, economic, and cultural factors, such the fam-
ily context, as well as individual factors, such as acceptance of the
result or the desire for a second opinion. There is lack of consensus
on the impact that offering rapid ARTmay have on these individ-
ual factors (Black 2013; Black 2014; Katirayi 2016).
By increasing the number of PLWH starting treatment, rapid ART
could increase the absolute number of people retained in care and
adhering to treatment. However, initiating rapid ART in PLWH
before all baseline screening test results (for opportunistic infec-
tions and renal function) are available could result in a higher lost
to follow-up (LTFU) rate (Abay 2015; Chan 2016; Pilcher 2017).
This could also result in a higher frequency of regimen modifica-
tion in those being offered rapid ART initiation (Pilcher 2017).
Finally, rapid ART could also increase the number of PLWH
achieving viral suppression through rising numbers of PLWH re-
ceiving ART, being engaged in care, and adhering to treatment
(Pilcher 2017; Rosen 2016). As ART is started earlier, viral sup-
pression could be achieved faster in those receiving rapid ART,
having a positive impact on HIV transmission and HIV-related
morbidity and mortality (Eshleman 2017; Lesko 2016).
Why it is important to do this review
With universal ARTbeing recommended and adopted worldwide,
interventions aimed to address poor linkage of care are increasingly
relevant. One of these proposed interventions is rapid initiation
of ART.
Although it has been suggested that rapid ART initiation could
improve engagement in care and increase rates of viral suppression
(Rosen 2016), there is conflicting evidence regarding the accept-
ability and appropriateness of this intervention. Although quali-
tative and observational studies have found greater than 90% ac-
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ceptance rates among PLWH who were offered rapid ART (Black
2013; Pilcher 2017), several other studies have found that issues,
such as denial, shock, difficulty committing to life-long treatment,
or the need to consult with a partner, may, in addition to other
known barriers, hamper the uptake or adherence to rapid ART
initiation (Black 2014; Katirayi 2016). Most of these studies have
focused on pregnant women receiving same-day ART under Op-
tion B+ of the WHO’s programme to prevent mother-to-child
transmission of HIV. This option was introduced by the WHO
in 2011 and offers pregnant women lifelong treatment as opposed
to previous approaches where ART was offered for a limited time
(Table 1) (UNICEF 2012). Although pregnant women constitute
a distinct group with unique motivations for taking ART, the bar-
riers identified in this group may be relevant to other settings.
Another area of concern is that with expedited ART initiation,
laboratory test results for opportunistic infection screening and
renal function may not be available at the time of treatment ini-
tiation, which may have a negative impact on the incidence of
adverse events, including drug side effects, regimen changes, and
the incidence of IRIS (Abay 2015; Pilcher 2017).
The WHO now recommends initiation of ART within one week
of diagnosis for those who are ready (WHO 2017a). Evidence for
the rapid initiation ofARTwas investigated in 2017 in a systematic
review (Ford 2018). Since the publication of this review, however,
new studies have been published that address rapid initiation of
ART in the context of complex interventions.Given the emergence
of this new evidence, a rigorous appraisal of the current literature,
including complex interventions and using established Cochrane
methods, will help to clarify the role of rapid ART initiation in
HIV care. We also aim to describe the complexity of the above-
mentioned interventions, in order to help readers understand the
context in which rapid initiation of ART has been evaluated.
O B J E C T I V E S
To assess the effects of rapid initiation of ART on treatment out-
comes and mortality in PLWH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all RCTs in which the unit of randomization is ei-
ther the individual or a cluster. We will not include non-random-
ized studies as we anticipate there to be a significant evidence base
from randomized studies. Additionally, any effect seen in non-
randomized studies is likely to be confounded due to the nature
of the intervention.
Types of participants
Inclusion criteria
We will include:
• adults (aged > 19 years), adolescents (aged > 10 to 19 years)
and children (aged 1 to 10 years) with a positive HIV test who
are known not to have previously received ART;
• pregnant women who are receiving life-long ART for their
own health (Option B+ of the WHO system) (WHO 2012).
Exclusion criteria
We will exclude:
• infants (aged 0 to < 1 years);
• pregnant women not receiving life-long ART for their own
health.
These groups will be excluded because they may receive ART as
part of prevention of mother to child transmission programmes,
which do not include life-long ART. For example, under WHO’s
Options A and B-, pregnant women with high CD4 cell counts
and infants receive only a short course of antiretrovirals (WHO
2012); hence, linkage to care and retention in HIV services differ
in comparison with other PLWH.
Types of interventions
Experimental interventions
Any intervention that aims to initiate life-long ART within seven
days of HIV diagnosis. This may be combined with several other
services, including education, counselling, addressing social de-
terminants, clinical and laboratory assessments, or treatment of
comorbid conditions.
Comparator interventions
Comparison interventions should offer the standard package of
HIV care. The same CD4/clinical stage thresholds for ART initia-
tion should be used in both intervention and comparison groups.
Cointerventions
We will include studies in which rapid ART initiation is offered
within a package of care alongside other cointerventions, even
if these are not provided in the comparator group. We will take
into account the differences between the package of care in the
intervention and comparator arms in our analyses (see Sensitivity
analysis).
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Types of outcome measures
Primary outcomes
• All-cause mortality rate;
• virological suppression 12 months after a positive HIV test.
According to WHO, viral suppression refers “to a viral load
below the detection threshold using viral assays” (WHO 2016).
There is inconsistency in the thresholds used by different
countries to define viral suppression (AIDSinfo 2015; EACS
2017; NASCOP 2016; NDOHSA 2015), which is due to the
variable sensitivity and specificity of the different HIV-viral load
assays available in the market (Sollis 2014; Swenson 2014). For
this reason, we will use the investigators’ trial definitions of
virological suppression or undetectable viral load.
Secondary outcomes
• Retention in HIV care at 12 months after a positive HIV
test. We define retention according to WHO guidelines, as
PLWH “who are enrolled in HIV care and routinely attend these
services in accordance to their needs” (WHO 2016). This
definition excludes those PLWH who either die or are LTFU. We
will consider the follow-up period to start at the point of
randomization to the intervention or comparator arm of any
study. There is a lack of consensus on the period of time that a
PLWH has to be disengaged with HIV services to be considered
LTFU, usually ranging from 3 to 6 months after the last
attendance to services (Hønge 2013; Pilcher 2017). A systematic
review that analysed the sensitivity and specificity of LTFU
thresholds in 41 countries concluded that the most appropriate
definition would be failure to engage with services for > 180 days
after the last visit (Chi 2011). Due to the variability and lack of a
standard definition, we will use the investigators’ trial definitions
of LTFU and we will explore, if possible, different LTFU
thresholds in our sensitivity analyses;
• uptake of ART, defined as the proportion of eligible PLWH
initiated on ART;
• ART adherence, as documented by self-report and/or pill
count and/or pharmacy refills and/or real-time electronic
monitors such as MEMScaps or Wisepill (Pellowski 2014);
• incidence of IRIS, as defined by the study authors. We will
include both paradoxical and unmasking IRIS (AIDSinfo 2017);
• incidence of treatment modification, defined as the number
and proportion of PLWH on ART who experience a regimen
modification in the intervention and control groups.
Adverse outcomes
We will analyse the number and proportion of PLWH experienc-
ing adverse drug reactions associated with ART in the intervention
and control groups, the number of cases of IRIS in the interven-
tion and control groups, and the number of HIV-negative people
partnered with a HIV-positive person who became HIV infected
during the study in each group.
Search methods for identification of studies
Electronic searches
Databases
We will search the following databases for relevant studies using
terms listed in Appendix 1:
• the Central Register of Controlled Trials (CENTRAL);
• Cochrane Database of Systematic Reviews (CDSR);
• MEDLINE (PubMed);
• Embase (Ovid);
• African Index Medicus (AIM);
• Latin American and Caribbean Health Sciences Literature
(LILACS);
• Web of Science (Core Collection).
There will be no restriction on date, language, or publication sta-
tus.
International trial registries
We will search the following registries for unpublished or ongoing
studies:
• ClinicalTrials.gov (www.clinicaltrials.gov);
• WHO International Clinical Trials Registry Platform (
apps.who.int/trialsearch/).
Searching other resources
Grey literature
We will search the following sources of grey literature to iden-
tify any relevant unpublished literature, including conference ab-
stracts:
• International AIDS Society Online Resource Library (
library.iasociety.org/GlobalSearch.aspx);
• websites of the International AIDS Conference (IAS) on
HIV science, the AIDS conference, the International Conference
on AIDS and STIs in Africa (ICASA), and the Conference on
Retroviruses and Opportunistic Infections (CROI) for the years
2013, 2014, 2015, and 2016;
• the RAND publication database (www.rand.org/
search.html).
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Reference lists
We will handsearch the reference lists of all included studies and
relevant systematic reviews to identify additional studies (for ex-
ample, unpublished or in-press citations).
Correspondence
We will contact trialists and subject experts for information on
unpublished or ongoing studies, or to request additional trial data.
Data collection and analysis
Selection of studies
We will merge studies identified by the keyword searches of differ-
ent databases and remove duplicate reports. Two review authors
will independently evaluate all the studies by reading the abstracts
to identify potentially relevant studies. We will obtain full-text
copies of those articles that are potentially eligible and we will
further decide on whether the studies meet the inclusion criteria
with the aid of an amended version of the study eligibility form
available at Cochrane 2017b (see Appendix 2). We will resolve all
disagreements by consulting a third review author. We will list all
studies excluded after full-text assessment in a ‘Characteristics of
excluded studies’ table. We will illustrate the study selection pro-
cess in a PRISMA diagram.
Data extraction and management
Two review authors will independently extract data from included
studies using a prepiloted data collection tool. We will resolve
any discrepancies by discussion, consulting a third review author
if necessary. If there are any missing data, we will contact the
original study authors. Data points for extraction will include the
following:
• methods: study aim, design, unit of allocation, method of
allocation, and duration of study. For cluster-randomized trials
we will extract the unit of analysis, the method of analysis, the
average cluster size, and the intraclass correlation coefficient
(ICC);
• participants: setting, number, inclusion/exclusion criteria,
participant’s sociodemographic characteristics, method of
recruitment, withdrawals, and losses to follow-up;
• intervention and control: number of participants/clusters
randomized to intervention and control, description of
intervention and control, including time of ART initiation,
eligibility criteria, and complexity of intervention;
• outcomes: definition of outcome, method of measurement,
time points measured, person measuring, unit of measurement,
statistical power, and imputation of missing data;
• other: ethical approval, information consent, source of
finding, and possible conflicts of interests.
Assessment of risk of bias in included studies
Two review authors will examine the components of each in-
cluded study for risk of bias using the Cochrane ‘Risk of bias’
tool (Cochrane 2017a). This includes detailed information on
sequence generation, allocation concealment, blinding (partic-
ipants, personnel, and outcome assessor), incomplete outcome
data, selective outcome reporting, and other sources of bias
(Higgins 2011). If any cluster-randomized trial is included in the
review, we will also assess the risk of bias by including the five ad-
ditional criteria specified in Section 16.3.2 of the Cochrane Hand-
book of Systematic Reviews of Interventions (Higgins 2011). We will
assess the methodological components of the studies and classify
these as adequate (low risk of bias), inadequate (high risk of bias),
or unclear, as explained in the Cochrane Handbook of Systematic
Reviews of Interventions (Higgins 2011).
We will also assess and report the likely magnitude and direction
of biases and their likely impact on the findings. We will resolve
any discrepancies by discussion or by consulting a third review
author. Where our judgement is uncertain we will attempted to
contact the study authors.
Measures of treatment effect
Dichotomous data
Wewill report outcomemeasures for dichotomous data (for exam-
ple, viral suppression yes/no) as risk ratios with 95% confidence
intervals (CIs).
Continuous data
If studies report any outcome measures as continuous data (for
example, viral load in copies per mL) we will report them using
mean differences with standard deviations.
Time-to-event data
If possible, we will analyse outcomes using hazard ratios with 95%
CIs. If trialists report the status of all the participants at a fixed
time-point (for example, 10 or 12 months) we will analyse the
results as dichotomous data by generating a 2 x 2 table, with the
estimate effects being risk ratios.
Timing of outcome assessment
For the outcomes of virological suppression and retention in care
at 12months, we will accept the result closest to 12 months within
a range of six to 14 months.
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For the secondary outcomes of incidence of treatment modifica-
tion and of number of people experiencing adverse drug events we
will accept the result closest to 12 months within a range of 6 to
14 months.
Unit of analysis issues
Cluster-randomized trials
Where cluster-randomized trials have appropriately adjusted for
the effects of clustering in their analysis we will use these adjusted
effect estimates and standard errors in our meta-analysis using the
generic inverse-variance method in Review Manager 5 (RevMan
5) (RevMan 2014).
If the included study does not perform any adjustment for clus-
tering, we will adjust the raw data ourselves using the ICC. If the
study authors do not report an ICC value in the published article,
we will either obtain this value from similar studies or we will esti-
mate the ICC value. We will not present results from cluster-ran-
domized trials that are not adjusted for clustering. If we estimate
the ICC value, we will perform sensitivity analyses to investigate
the robustness of our analyses.
Cross-over trials
We do not anticipate any cross-over trials addressing this review
question.
Repeated observations on participants
In some studies, results from more than one timepoint may be
reported. In those cases we will conduct separate analyses accord-
ing to the different outcomes defined (see Primary outcomes;
Secondary outcomes). For example, if viral suppression is reported
at six and 12 months, we will conduct two separate analyses, one
for the secondary outcome of viral suppression at six months and
another for the primary outcome of viral suppression at 12months.
Studies with multiple treatment groups
Depending on the study,wewill addressmultiple treatment groups
in the analysis in one of three ways:
• combining groups to create a single pair-wise comparison;
• selecting one pair of interventions and excluding the others;
• splitting the ‘shared’ group into two or more groups with a
smaller sample size and including two or more (reasonably
independent) comparisons.
Dealing with missing data
Where possible, we will contact the original authors to request
missing data. If, after contacting the authors, there are still missing
data and we consider the data to be missing at random, we will
include only the data available in the analysis. If we do not consider
the data to be missing at random, we will impute the missing
data and account for the fact that the data were imputed with
uncertainty, following the advice in the Cochrane Handbook of
Systematic Reviews of Interventions (Higgins 2011). We will then
conduct a sensitivity analysis to analyse how sensitive the results
are to the assumptions we made when imputing missing data.
We will analyse all data as intention-to-treat.
Assessment of heterogeneity
We will assess the statistical heterogeneity in each meta-analysis
by inspecting forest plots and calculating Chi2 test values and I2
statistics. We will consider significant heterogeneity to be present
if the P value of the Chi2 test is < 0.10. We will interpret the I2
statistic according to the thresholds recommended in theCochrane
Handbook of Systematic Reviews of Interventions (Higgins 2011):
• 0% to 40%: low heterogeneity;
• 30% to 60%: moderate heterogeneity;
• 50% to 90%: substantial heterogeneity;
• 75% to 100%: considerable heterogeneity.
We will explore the causes of statistical heterogeneity by conduct-
ing a subgroup analysis or meta-regression. We will also explore
clinical and methodological heterogeneity by assessing trial popu-
lations, methods used, and interventions delivered.
Assessment of reporting biases
If we include more than 10 studies we will perform a funnel plot
to explore reporting bias. We will assess reporting bias a visual
exploration of the funnel plot and by conducting an appropriate
statistical test for asymmetry (for example, Begg or Egger tests)
following the advice given in the Cochrane Handbook of Systematic
Reviews of Interventions (Higgins 2011).
Data synthesis
We will analyse data using RevMan 5 (RevMan 2014). We will
assess the clinical, methodological, and statistical heterogeneity of
the trials. If we identify considerable heterogeneity, we will explore
the causes by carrying out subgroup analyses or meta-regression.
If, after exploring heterogeneity, we identify considerable unex-
plained heterogeneity, we will consider not combining the results
in a meta-analysis. If we identify low or moderate heterogeneity,
we will combine the results using a random-effects model. If we
find no heterogeneity, we will combine the results using a fixed-
effects model.
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Subgroup analysis and investigation of heterogeneity
If we include a sufficient number of trials, we plan to carry out
the following subgroup analyses to investigate potential sources of
heterogeneity.
• Severity of HIV infection at baseline, defined by CD4 cell
count:
◦ CD4 cell count > 200 copies/mL;
◦ CD4 cell count < 200 copies/mL.
• Time of ART initiation in the intervention group:
◦ same-day ART (< 24 hours post-ART eligibility);
◦ ART initiated between > 24 hours and < 7 days post-
ART eligibility.
• Age group:
◦ children (aged 1 to 10 years);
◦ adolescents (aged > 10 to 19 years);
◦ adults (aged > 19 years).
• Geographical location, defined by the World Bank’s income
classification of countries (World Bank 2017):
◦ low and low-middle income countries;
◦ high and upper-middle income countries.
Sensitivity analysis
We plan to conduct sensitivity analyses to investigate the effect on
the outcomes of:
• including and excluding trials we consider to be at high risk
of bias for random sequence generation according to Cochrane’s
‘Risk of bias’ assessment;
• analysing the different assumptions made when imputing
missing data;
• analysing retention in care using different LTFU thresholds.
If we identify, during the review process, any issues that are suitable
for sensitivity analysis, we will include them in this section, as
recommended in the Cochrane Handbook of Systematic Reviews of
Interventions (Higgins 2011).
In studies in which rapid ART initiation is delivered as a package
of care alongside other cointerventions that are not present in the
comparator arm, we will consider not pooling the results if such
cointerventions may confound the effect estimate.
‘Summary of findings’ table
We will create a ‘Summary of findings’ table using GRADEpro
software (GRADEpro 2015). In the table, we will display the pri-
mary and secondary outcomes of the review (see Types of outcome
measures), the comparative risks between intervention and control
groups, the relative effects with 95% CIs, the number of partici-
pants in the studies, and the quality of evidence. We will classify
the strength of the evidence for each of the outcomes as high,mod-
erate, low, or very low, according to a quality assessment using the
five criteria (limitations, inconsistency, indirectness, imprecision,
and publication bias) of the GRADE system (GRADE 2004).
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A D D I T I O N A L T A B L E S
Table 1. Antiretroviral treatment and prophylaxis for pregnant women according to the WHO Prevention of mother-to-child
transmission programmes
Options Treatment for pregnant women with CD4 count < 350
cells/mm³
Prophylaxis for pregnant women with CD4 count >
350 cells/mm³
Option A ART started as soon as HIV is diagnosed, continued for
life
Antivirals started as soon as 14 weeks of gestation and con-
tinued until 7 days post-partum
Option B ART started as soon as HIV is diagnosed, continued for
life
Antivirals started as soon as 14 weeks of gestation until
childbirth if not breastfeeding or until one week after ces-
sation of breastfeeding
Option B+ ART initiated as soon as HIV diagnosis and continued for life
Source: WHO 2012.
A P P E N D I C E S
Appendix 1. MEDLINE (PubMed) search strategy
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Search Query
#11 Search #5 AND #8 AND #9 AND #10
#10 Search #3 OR #4
#9 Search #1 OR #2
#8 Search #6 NOT #7
#7 Search animals [Mesh] NOT humans [Mesh]
#6 Search ((((((randomized controlled trial [pt]) OR controlled clinical trial [pt]) OR randomized [tiab]) OR placebo [tiab])
OR clinical trials as topic [mesh: noexp] OR randomly [tiab]) OR trial [tiab])
#5 Search Immediate OR rapid OR same-day OR “same day” OR fast-track OR “fast track” OR universal OR “test and treat”
OR early OR accelerat* OR instant OR prompt OR fast OR quick OR expedit*
#4 Search antiretroviral agents [Mesh] OR antiretroviral therapy, highly active [Mesh]
#3 Search Antiretroviral* OR ((anti) AND (retroviral*)) OR ARV* OR ART OR “antiretroviral therapy” OR HAART OR (
(highly) AND (active) AND (antiretroviral*) AND (therap*)) OR ((anti) AND (hiv)) OR ((anti) AND (acquired immun-
odeficiency)) OR ((anti) AND (acquired immuno-deficiency)) OR ((anti) AND (acquired immune-deficiency)) OR ((anti)
AND (acquired immun*) AND (deficienc*))
#2 Search HIV infections [MeSH] OR HIV [MeSH]
#1 SearchHIVORhiv-1ORhiv-2*ORhiv1ORhiv2ORhiv infect*ORhuman immunodeficiency virusORhuman immune
deficiency virus OR human immuno-deficiency virus OR human immune-deficiency virus OR ((human immun*) AND
(deficiency virus)) OR acquired immunodeficiency syndromes OR acquired immune deficiency syndrome OR acquired
immuno-deficiency syndrome OR acquired immune-deficiency syndrome OR ((acquired immun*) AND (deficiency syn-
drome)) OR HIV/AIDS
This is the preliminary search strategy for MEDLINE (PubMed). We will adapt it for other electronic databases. We will report all
search strategies in full in the final version of the review.
Appendix 2. Study eligibility form
Review title or
ID
Study ID
Report ID
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(Continued)
Date form com-
pleted (dd/mm/
yyyy)
Study
characteristics
Eligibility criteria Eligibility criteria met? Location in text or source (page and para-
graph/fig/table/other)
Yes No Unclear
Type of study Randomized controlled
trial or cluster-random-
ized trial
Participants HIV positive adults,
adolescents, children or
pregnant women tak-
ing antiretroviral ther-
apy (ART) for their own
health
Types of inter-
vention
Rapid ART (defined as
receiving antiretroviral
therapy within 7 days
of HIV diagnosis) plus
usual care (for example,
counselling,
opportunistic infection
screening)
Types of com-
parison
Delayed ART (defined
as receiving antiretrovi-
ral therapy at any time
after 7 days post-HIV
diagnosis) plus usual
care
Types of out-
come measures
Viral suppression at 12
months and/or renten-
tion in care at 12
months and/or uptake
of ART and/or inci-
dence of IRIS and/or
incidence of regimen
change
INCLUDE (Yes/
No):
EXCLUDE (Yes/No):
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(Continued)
Reason for exclu-
sion
Notes:
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